Deferasirox

Deferasirox
Clinical data
Pronunciation	de FER a sir ox
Trade names	Exjade, others
Other names	CGP-72670, ICL-670A, IC L670
AHFS/Drugs.com	Monograph
MedlinePlus	a606002
License data	US DailyMed: Deferasirox;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	V03AC03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	70%
Protein binding	99%
Metabolism	Liver glucuronidation
Elimination half-life	8 to 16 hours
Excretion	Fecal (84%) and kidney (8%)
Identifiers
	IUPAC name 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid;
CAS Number	201530-41-8 ;
PubChem CID	214348;
DrugBank	DB01609 ;
ChemSpider	4591431 ;
UNII	V8G4MOF2V9;
KEGG	D03669 ;
ChEBI	CHEBI:49005;
ChEMBL	ChEMBL550348 ;
CompTox Dashboard (EPA)	DTXSID1048596 ;
ECHA InfoCard	100.211.077
Chemical and physical data
Formula	C21H15N3O4
Molar mass	373.368 g·mol−1
3D model (JSmol)	Interactive image;
Density	1.4±0.1 g/cm3
	SMILES OC(=O)c1ccc(cc1)n2nc(nc2c3ccccc3O)c4ccccc4O;
	InChI InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28) ; Key:BOFQWVMAQOTZIW-UHFFFAOYSA-N ;
	(what is this?) (verify)

Deferasirox, sold under the brand name Exjade among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose.

It was approved by the US Food and Drug Administration (FDA) in November 2005. According to the FDA (May 2007), kidney failure and cytopenias have been reported in patients receiving deferasirox tablets for oral suspension. It is approved in the European Union by the European Medicines Agency (EMA) for children six years and older for chronic iron overload from repeated blood transfusions. It is on the World Health Organization's List of Essential Medicines.

In July 2020, Teva decided to discontinue deferasirox. It is available as a generic medication.